AtriCure, Inc. ATRC R2K
Company Overview
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Why Investors Should Care
Revenue has grown at a 16.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.15.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $534.53M (+14.9% YoY).
- Trailing 12 Months Year-on-year growth — revenue +14.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.44% |
| 1 Year: | 14.30% |
Stock Price Performance
| 1 Year: | +9.65% |
| 6 Months: | -17.22% |
| 3 Months: | +19.75% |
| 1 Month: | +20.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)68.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.4% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATRC AtriCure, Inc. R2K | 34.32 | -343.20 | $1.74B | 0.00% | -1.65% | -0.97% | 16.44% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 42.15M | - | 46.99M | 51.80M | 49.94M | 52.89M | 53.97M | 58.91M | 56.61M | 61.32M | 53.23M | 40.82M | 54.76M | 57.73M | 59.27M | 71.38M | 70.46M | 73.22M | 74.58M | 84.53M | 83.25M | 93.49M | 100.92M | 98.29M | 108.85M | 116.27M | 115.91M | - | 123.62M | 136.14M | 134.27M | 140.50M | 141.25M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.99M | 34.66M | 32.94M | 35.16M | 31.94M |
| Gross Profit | 25.55M | 25.91M | 28.82M | 27.47M | 28.90M | 30.01M | 32.55M | 30.92M | 32.68M | 34.50M | 38.08M | 35.95M | 38.59M | 39.87M | 43.89M | 41.80M | 44.77M | 38.88M | 27.65M | 40.33M | 42.44M | 44.54M | 54.08M | 52.23M | - | 55.59M | 63.52M | 61.71M | 69.61M | 77.08M | 73.87M | 81.27M | 86.84M | 86.79M | - | 92.63M | 101.48M | 101.33M | 105.34M | 109.31M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 98.58M | 107.67M | 101.12M | 102.85M | 108.78M |
| Operating Income | -10.63M | -9.42M | -7.74M | -6.29M | -7.70M | -9.64M | -6.36M | -6.85M | -2.13M | -9.43M | 958.00K | -6.05M | -2.61M | -5.32M | -3.84M | -8.64M | -15.33M | -15.45M | -7.29M | -3.99M | -17.50M | -15.88M | -15.08M | 98.67M | - | -14.15M | -13.66M | -10.72M | -5.78M | -4.14M | -8.09M | -10.92M | -7.17M | -7.41M | - | -5.95M | -6.19M | 208.00K | 2.49M | 526.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.00K | 732.00K | 6.55M | 8.97M | 7.01M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.42M | 1.49M | 1.47M | 1.50M | 1.34M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.51M | -5.93M | -86.00K | 2.36M | 394.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 239.00K | 261.00K | 181.00K | 604.00K | 286.00K |
| Net Income | -10.91M | -9.72M | -8.21M | -6.78M | -8.62M | -10.18M | -6.88M | -7.25M | -2.58M | -10.13M | -338.00K | -7.24M | -3.43M | -5.63M | -4.10M | -9.36M | -16.10M | -16.41M | -8.24M | -4.95M | -18.56M | -16.92M | -16.25M | 97.11M | - | -15.18M | -14.84M | -12.27M | -6.48M | -5.12M | -9.05M | -13.27M | -8.01M | -7.85M | - | -6.75M | -6.19M | -267.00K | 1.76M | 108.00K |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.11 | - | -0.38 | -0.36 | 2.11 | - | -0.33 | -0.32 | -0.27 | -0.14 | -0.11 | -0.20 | -0.28 | -0.17 | -0.17 | - | -0.14 | -0.13 | -0.01 | 0.04 | 0.00 |
| R&D Expense | - | 8.56M | 9.12M | 8.27M | - | 9.55M | 8.91M | 7.97M | - | 9.06M | 8.65M | 8.56M | - | 8.18M | 9.80M | 10.15M | - | 11.59M | 10.04M | 10.58M | - | 11.22M | 12.20M | 11.28M | - | 13.63M | 14.79M | 15.17M | 15.33M | 17.44M | 20.35M | 19.84M | 20.42M | 20.96M | - | 22.53M | 29.28M | 22.89M | - | 24.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.53M | 59.01M | 64.40M | 70.25M | 81.89M | 107.45M | 129.75M | 155.11M | 174.72M | 201.63M | 230.81M | 206.53M | - | 330.38M | 399.25M | 465.31M | 534.53M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 84.44M | 98.88M | 117.78M | 133.75M |
| Gross Profit | 41.78M | 45.39M | 47.00M | 50.01M | 59.56M | 75.75M | 92.88M | 111.10M | 126.16M | 147.12M | 170.34M | 149.31M | - | 245.94M | 300.37M | 347.52M | 400.78M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 288.61M | 327.05M | 387.54M | 410.23M |
| Operating Income | -15.51M | -3.19M | -4.73M | -7.20M | -10.89M | -16.36M | -26.72M | -31.14M | -24.98M | -17.13M | -33.12M | -44.23M | - | -42.67M | -26.68M | -40.01M | -9.45M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.50M | -8.11M | -18.53M | 16.25M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.99M | 6.92M | 6.41M | 5.88M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -46.20M | -29.85M | -43.67M | -10.16M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 268.00K | 591.00K | 1.02M | 1.28M |
| Net Income | -16.49M | -3.79M | -5.46M | -7.53M | -11.46M | -16.21M | -27.21M | -33.34M | -26.89M | -21.14M | -35.19M | -48.16M | 50.20M | -46.47M | -30.44M | -44.70M | - |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.94 | -1.14 | - | -1.02 | -0.66 | -0.95 | -0.24 |
| R&D Expense | 11.41M | 11.53M | 11.86M | 12.15M | 13.44M | 18.60M | 25.74M | 35.82M | 34.14M | 34.72M | 41.23M | 43.07M | 48.51M | 57.34M | 73.92M | 96.18M | 99.21M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Jan 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 33.72M | 33.86M | 32.43M | 111.95M | 158.40M | 273.09M | 276.42M | 267.70M | 356.76M | 557.88M | 714.54M | - | 585.45M | 613.93M | - | 609.33M | 654.18M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 215.21M | 266.25M | - | 267.83M | 322.52M |
| Cash & Equivalents | 11.45M | 8.90M | 4.23M | 9.76M | 7.75M | 14.89M | 28.38M | 23.76M | 24.21M | 21.81M | 32.23M | 28.48M | 41.94M | - | 58.10M | 84.31M | - | 122.72M | 167.43M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.93M | 67.90M | - | 75.33M | 78.49M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.69M | 52.50M | - | 60.34M | 66.65M |
| Total Liabilities | - | - | 16.98M | 18.24M | 19.93M | 39.34M | 25.87M | 86.41M | 107.98M | 106.54M | 107.38M | 310.54M | 302.14M | - | 128.69M | 147.76M | - | 148.36M | 162.24M |
| Current Liabilities | - | - | 13.04M | 10.81M | 12.21M | 26.71M | 25.64M | 31.59M | 28.83M | 31.90M | 40.22M | 49.92M | 49.14M | - | 58.39M | 74.57M | - | 73.42M | 81.52M |
| Long Term Debt | - | - | - | - | - | - | - | - | 23.89M | 24.10M | 35.57M | 59.63M | 53.44M | - | 56.83M | 60.59M | 61.00M | 61.87M | 61.87M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.55M | 74.49M | - | 73.72M | 73.38M |
| Total Equity | 29.12M | 17.09M | 16.74M | 15.62M | 12.50M | 72.60M | 132.54M | 186.69M | 168.44M | 161.17M | 249.38M | 247.34M | 412.39M | - | 456.75M | 466.17M | - | 460.97M | 491.94M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.56M | 47.53M | - | 48.87M | 49.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 419.95K | -33.00K | -1.99M | -1.94M | -5.22M | - | -7.84M | -15.12M | -8.94M | -4.17M | -15.81M | -19.87M | - | -22.14M | 4.48M | 12.20M | 57.33M |
| Investing Cash Flow | -2.17M | -3.33M | 2.72M | -2.80M | -14.15M | - | -10.50M | -12.08M | 3.76M | -85.40M | -2.15M | -156.20M | - | 44.01M | 21.82M | 30.23M | -14.55M |
| Financing Cash Flow | -914.01K | -1.44M | 4.85M | 2.66M | 26.83M | - | 13.96M | 27.70M | 2.76M | 100.18M | 14.37M | 189.39M | - | -7.06M | -32.00K | -3.60M | 1.18M |
| Capital Expenditure | -1.36M | -1.81M | -1.52M | -2.98M | -2.86M | -5.51M | -13.45M | -7.69M | -6.38M | -6.21M | -12.18M | -5.26M | - | -16.88M | -42.00M | -23.46M | -15.05M |
| Free Cash Flow | -940.51K | -1.85M | -3.51M | -4.92M | -8.09M | - | -21.29M | -22.81M | -15.33M | -10.38M | -27.99M | -25.13M | - | -39.02M | -37.51M | -11.26M | 42.28M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.81M | 26.27M | 38.84M | 43.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 76.6% | 76.9% | 73.0% | 71.2% | 72.7% | 70.5% | 71.6% | 71.6% | 72.2% | 73.0% | 73.8% | 72.3% | - | 74.4% | 75.2% | 74.7% | 75.0% |
| Operating Margin % | -28.4% | -5.4% | -7.3% | -10.2% | -13.3% | -15.2% | -20.6% | -20.1% | -14.3% | -8.5% | -14.4% | -21.4% | - | -12.9% | -6.7% | -8.6% | -1.8% |
| Net Margin % | -30.2% | -6.4% | -8.5% | -10.7% | -14.0% | -15.1% | -21.0% | -21.5% | -15.4% | -10.5% | -15.2% | -23.3% | - | -14.1% | -7.6% | -9.6% | - |
| ROE % | -96.5% | -22.7% | -34.9% | -60.3% | -15.8% | -12.2% | -14.6% | -19.8% | -16.7% | -8.5% | -14.2% | -11.7% | - | -10.2% | -6.5% | -9.7% | - |
| ROCE % | - | -15.4% | -20.5% | -35.6% | -12.8% | -12.3% | -11.1% | -12.6% | -10.6% | -5.4% | -6.5% | -6.6% | - | -8.1% | -4.9% | -7.5% | -1.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.98% | 4.04M | $129.20M |
| 2 | Wellington Management Group, LLP | 6.68% | 3.38M | $108.11M |
| 3 | Alliancebernstein L.P. | 6.44% | 3.26M | $104.15M |
| 4 | Hood River Capital Management LLC | 6.16% | 3.12M | $99.64M |
| 5 | Vanguard Portfolio Management LLC | 5.34% | 2.70M | $86.38M |
| 6 | Vanguard Capital Management LLC | 4.26% | 2.16M | $68.90M |
| 7 | Nomura Asset Management International Inc | 3.56% | 1.80M | $57.69M |
| 8 | Goldman Sachs Group Inc | 3.29% | 1.67M | $53.28M |
| 9 | Marshall Wace LLP | 2.90% | 1.47M | $46.90M |
| 10 | State Street Corporation | 2.57% | 1.30M | $41.62M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATRC
AtriCure to Announce Second Quarter 2026 Financial Results
MASON, Ohio, July 02, 2026--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced …
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.…
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
A Look At AtriCure (ATRC) Valuation As BoxX NoAF Trial Acceleration Draws Investor Attention
AtriCure (ATRC) has accelerated its BoxX-NoAF clinical trial by 12 months, with patient enrollment now targeted for completion by year end. This development is drawing fresh attention from investors assessing the stock’s risk reward profile…
AtriCure (ATRC) Advances Key Heart Disease Trial 12 Months Ahead of Schedule
AtriCure, Inc. (NASDAQ:ATRC) is one of the top small cap stocks with huge growth potential. On May 6, Needham reiterated its Buy rating and $45 price target on AtriCure, Inc. (NASDAQ:ATRC) after the company delivered blowout Q1 2026 earning…
ATRC — Frequently Asked Questions
What is the current share price of AtriCure, Inc. (ATRC)?
As of 2026-07-14 21:23 PDT, AtriCure, Inc. (ATRC) trades at $34.32 on NasdaqGM. Its 52-week range is $25.86 to $42.41.
What is the market capitalisation of ATRC?
AtriCure, Inc. (ATRC) has a market capitalisation of $1.74B on NasdaqGM.
What is the P/E ratio of ATRC?
ATRC trades at a trailing price-to-earnings (P/E) ratio of -343.20. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.96.
What is the return on equity (ROE) of ATRC?
ATRC has a return on equity (ROE) of -0.97%. Its return on capital employed (ROCE) is -1.65%.
Is ATRC a good stock to buy?
This page provides a data-driven analysis of AtriCure, Inc. (ATRC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.